Peripheral blood progenitor cell collection in low-weight children

Journal of Hematotherapy and Stem Cell Research

Volumn 11, Issue 4, 2002, Pages 633-642

  Sevilla, Julián ^a   González Vicent, Marta ^a   Madero, Luis ^a   Díaz, Miguel Angel ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; CYTAPHERESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKAPHERESIS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVIEW; SAFETY;

BLOOD COMPONENT REMOVAL; BODY WEIGHT; CHILD; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; THINNESS;

EID: 0036329356     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/15258160260194776     Document Type: Review

References (81)

1. Collection of peripheral blood stem cells in pediatric patients: A concise review on technical aspects
2. Using peripheral blood progenitor cells (PBPC) for transplantation in pediatric patients: A state-of-the-art review
3. Defining a therapeutic dose of peripheral blood stem cells
4. Factors that influence collection and engraftment of autologous peripheral-blood stem cells
5. + cell content
6. + cell dose
7. Clinical collection and use of peripheral blood stem cells in pediatric patients
8. Isolation and storage of peripheral blood hematopoietic stem cells for auto-transplantation into children with cancer
9. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man
10. Granulocyte-macrophage colony stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation
11. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor
12. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood
13. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
14. G-CSF and peripheral blood progenitor cells
15. G-CSF and peripheral blood progenitor cells
16. G-CSF and peripheral blood progenitor cells
17. Autotransplantation of peripheral blood stem cells mobilized by chemotherapy and recombinant human granulocyte colony-stimulating factor in childhood neuroblastoma and non-Hodgkin's lymphoma
18. Successful blood stem cell collection and transplant in children weighing less than 25 kg
19. + blood cells predicts the colony-forming capacity of leukapheresis products in children
20. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor
21. GCSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: Parameters affecting bone marrow engraftment
22. Use of G-CSF to mobilize peripheral blood stem cells for collection from children
23. Collection and transplantation of peripheral blood progenitor cells mobilized by G-CSF alone in children with malignancies
24. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis
25. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells
26. + selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer
27. Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF
28. Stem cell mobilization with G-CSF alone in breast cancer patients: Higher progenitor cell yield by delivering divided doses (2 × 5 μg/kg) compared to a single dose (1 × 10 μg/kg)
29. Mobilization and harvesting of peripheral blood stem cells: Randomized evaluations of different doses of filgrastim
30. Granulocyte colony-stimulating factor alone at 20 mg/kg vs 10 mg/kg for peripheral blood stem cell mobilization in children
31. Mobilization/harvest and transplantation with blood stem cells, manipulated or unmanipulated
32. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients
33. Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor
34. Use of concurrent GCSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells in children with malignant disease
35. Randomized comparison of GCSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: Effects on hematopoietic recovery after high-dose chemotherapy
36. Management strategies for the hard-to-mobilize patient
37. Analysis of the effect of prior therapy on progenitor cell yield: Use of a chemotherapy scoring system
38. Previous treatment predicts the efficiency of blood progenitor cell mobilisation: Validation of a chemotherapy scoring system
39. Allogeneic blood stem cell transplantation: Considerations for donors
40. Optimizing dose and scheduling of filgrastim (Granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers
41. Recommendations on the use of colony-stimulating factors in children: Conclusions of a European panel
42. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors
43. Allogeneic peripheral blood stem cell transplant in children
44. Efficacy of the mobilization of peripheral blood stem cells by granulocyte colony-stimulating factor in pediatric donors
45. Peripheral blood progenitor cell (PBPC) collection by large-volume leukapheresis from pediatric donors
46. Successful large volume leukapheresis on a small infant allogeneic donor
47. Donor age-related differences in PBPC mobilization with rHuG-CSF
48. Characterization of peripheral blood progenitor cells (PBPC) mobilized by filgrastim (rHuG-CSF) in normal volunteers: Dose-effect relationship for filgrastim with the character of mobilized PBPC
49. Mobilization of peripheral blood progenitor cells for allogeneic transplantation: Efficacy and toxicity of a high-dose rhG-CSF regimen
50. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation
51. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation
52. Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases
53. + peripheral blood progenitor cells in normal donors
54. Peripheral blood stem cell mobilization and apheresis: Analysis of adverse events in 94 normal donors
55. + cells: A pediatric experience
56. Safety of granulocyte colony-stimulating factor in normal donors
57. A cutaneous eruption from G-CSF in a healthy donor
58. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers
59. Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: A pilot study
60. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF
61. + cells by glycosylated and nonglycosylated G-CSF in healthy volunteers - A comparative study
62. Collection and use of peripheral blood stem cells in very small children
63. Large-volume leukapheresis for peripheral blood stem cell collection in children: A simplified single-apheresis approach
64. + cell dose in engraftment kinetics
65. Pediatric large volume peripheral blood progenitor cell collections from patients under 25kg: A primer
66. Peripheral blood stem cell (PBSC) collection in extremely low-weight infants
67. Collection and transplantation of peripheral blood stem cells in very small children weighing 20 kg or less
68. Feasibility of peripheral blood stem cell (PBSC) and peripheral blood mononuclear cell (PBMNC) separation in children with a body weight below 20 kg
69. Safe and efficient peripheral blood stem cell collection in the smallest of children
70. Peripheral blood progenitor cell collection by large-volume leukapheresis in low-weight children
71. The relation between the number of PBSC and number of leukapheresis in children
72. Intra-apheresis recruitment of blood progenitor cells in children
73. Large-volume leukapheresis for peripheral blood stem cell collection in patients with hematologic malignancies
74. + progenitors and colony-forming units-granulocyte macrophage are recruited during large-volume leukapheresis and concentrated by counterflow centrifugal elutriation
75. Kinetics of peripheral blood stem cell harvest during a single apheresis
76. Kinetics of standardized large volume leukapheresis (LVL) in patients do not show a recruitment phenomenon of peripheral blood progenitor cells (PBPC)
77. Large volume leukapheresis in pediatric patients: Processing more blood diminishes the apparent magnitude of intra-apheresis recruitment
78. Collection and recruitment of CD34+ cells during large-volume leukapheresis
79. Large-volume leukaphereses may be more efficient than standard-volume leukaphereses for collection of peripheral blood progenitor cells
80. Volume-dependent collection of peripheral blood progenitor cells during large-volume leukapheresis for patients with solid tumours and haematological malignancies
81. Kinetics of peripheral blood stem cell collection in large-volume leukapheresis for pediatric patients undergoing chemotherapy and adult patients before chemotherapy